Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760345 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7280516 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7280510 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7290562 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8866477 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8866479 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9601822 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1077181 | 0.66 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1077183 | 0.66 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16684711 | 0.65 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120253046-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-0770077-B1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | disclosed |
| EP-0770077-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-02 | — | — | EP | disclosed |
| US-5576434-A | (1-azabicyclo[2.2.2]oct-3-yl) (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)amine and n-(1-azabicyclo[2.2.2]oc | HELSINN HEALTHCARE SA (CH) | 1996-11-19 | — | — | US | disclosed |
| US-5567818-A | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein | SYNTEX (U.S.A.) INC. (US) | 1996-10-22 | — | — | US | disclosed |
| US-5492914-A | ADMINISTERING TO TREAT A CONDITION CHOSEN FROM EMESIS, PSYCHOSIS, ANXIETY/DEPRESSIVE STATE, HYPERTENSION, ARRHYTHMIA AND PAIN | SYNTEX (U.S.A.) INC. (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1996001824-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253046-A1 | PALONOSETRON METABOLITES | CYP3A5, MC2R, CYP21A2 | CHRNB2 2683/4885CHRNA4 1525/4885CHRNB4 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.